Powered by
MOMENTUM
MEDIA
Johnson Winter & Slattery advised on the public offering and listing of US-based AirXpanders on the ASX.
Firms: Johnson Winter & Slattery (AirXpanders), K&L Gates (Underwriter)
Value: $39.1 million
Area: Banking & finance
Key players: JWS M&A partner James Rozsa lead the deal.
Deal significance:
About $39.1 million was raised by an offering of CDIs into Australia, Singapore, Hong Kong and the UK, and through a parallel placement of shares in the US, according to a statement from JWS.
“The offers valued AirXpanders at approximately A$112.6 million following the raising, and ASX trading commenced on 22 June 2015,” the statement said. “The cash raised by the IPO will be used to increase manufacturing capability and ramping up sales and marketing efforts.”
AirXpanders is a medical device company focused on the design, manufacturing and distribution of a patient-controlled tissue expander used in patients undergoing breast reconstruction following mastectomy surgery.
Login
